Molecular Profiling of Advanced Soft-tissue Sarcomas
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
MULTISARC is a randomized multicenter study assessing whether high throughput molecular
analysis (next generation sequencing exome - NGS) is feasible in advanced/metastatic
soft-tissue sarcoma patients, that is, whether NGS can be conducted for a large proportion of
patients, with results available within reasonnable delays.
In parallel, MULTISARC aims to assess efficacy of an innovative treatment strategy guided by
high throughput molecular analysis (next generation sequencing exome, RNASeq [NGS]) in
patients with Advanced/metastatic soft-tissue sarcomas. At the end of first-line treatment,
participant's tumor profile of experimental Arm NGS (treatment strategy based on NGS results)
will be discussed within a multidisciplinary tumor board which aims at discussing the genomic
profiles and at providing a therapeutic decision for each participant. Participants for whom
a targetable genomic alteration has been identified will be proposed to enter in one of the
subsequent phase II single-arm sub-trial.
Phase:
Phase 3
Details
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators:
CIC-EC 1401/EUCLID Commissariat A L'energie Atomique EUCLID Clinical Trial Platform Institut Bergonié Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris Plateforme labellisée Inca - Institut Bergonié, Bordeaux Plateforme labellisée Inca – Hôpital Européen Georges Pompidou, Paris Plateforme labellisée Inca – Institut Bergonié, Bordeaux